Rectal Cancer Clinical Trial
— TEPIRECOfficial title:
Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
NCT number | NCT05772481 |
Other study ID # | 2022-007 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 19, 2023 |
Est. completion date | September 19, 2025 |
With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 19, 2025 |
Est. primary completion date | September 19, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) 0 to 2 - Histologically proven rectal cancer - clinical tumor classification (cT) : cT3 - cT4 or all T / N+ / M0 - Tumor resectable or considered resectable after chemoradiotherapy - Decision chemotherapy followed by neoadjuvant chemoradiotherapy decided at the organ Multidisciplinary Meeting - Absence of distant metastases - Adequate contraception for women of childbearing potential - Adequate hematologic function - Adequate liver function - Free, signed and informed consent - For women of childbearing potential : negative pregnancy test Exclusion Criteria: - Subject with Uncontrolled diabetes - Contraindication to surgery - Contraindication to MRI - Contraindication to PET scan - Contraindication to chemotherapy - History of pelvic radiotherapy - History of major co-morbidity that may prevent treatment and no active infection (HIV or chronic hepatitis B or C) - Hypofractionated radiotherapy according to the Swedish protocol (25 Gy in 5 fractions) - Colloid (mucinous) adenocarcinoma - Presence of distant metastases - Contraindication to 5-FluoroUracil (FU), oxaliplatin or irinotecan - History of known Gilbert's disease - Patient with known UGT1A1 genotype - Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency - Medical history of chronic diarrhea or inflammatory disease of the colon or rectum - Medical history of angina or myocardial infarction. - Active progressive infection or any other serious medical condition that could compromise the administration of the treatment - Other concurrent cancer, or medical history of cancer other than treated in situ cervical carcinoma or basal cell carcinoma or squamous cell carcinoma - Patient enrolled in another clinical trial testing an investigational agent - Pregnant or breastfeeding woman - Persons deprived of their freedom or under guardianship or incapable of giving consent - Any psychological, familial, sociological or geographic condition that may interfere with the study protocol or follow-up schedule |
Country | Name | City | State |
---|---|---|---|
France | Institut de cancérologie Strasbourg Europe | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
Institut de cancérologie Strasbourg Europe |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of metabolic criteria. | The purpose of this study is to determine predictive parameters for response to the first phase of treatment by accurately identifying the characteristics of tumors that have responded or not to chemotherapy and chemoradiotherapy. Metabolic criteria will be measured with the SUVmax values that will be determined on the 4 PET-MRI scans. |
At the surgery | |
Primary | Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of MRI criteria. | MRI criteria will be measured with the Apparent Diffusion Coefficient (ADC) values that will be determined on the 4 PET-MRI scans. | At the surgery | |
Primary | Description of the correlation between the PET-MRI changes after neo-adjuvant treatment and the histological response after surgery in terms of anatomopathological criteria. | Anatomopathological criteria will be measured with the histopathological response to treatment which will be defined according to the tumor regression grade (TRG) | At the surgery | |
Secondary | Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of tumor volumes | Record of tumor volumes on MRI PET 1 | At the PET MRI pretherapy (= PET MRI 1) | |
Secondary | Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of SUVmax values | Record of SUVmax on MRI PET 1 | At the PET MRI pretherapy (= PET MRI 1) | |
Secondary | Comparison of the first PET-MRI staging with standard of care imaging, namely pelvic MRI in terms of ADC values | Record of ADC on MRI PET 1 | At the PET MRI pretherapy (= PET MRI 1) | |
Secondary | Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta tumor volume | Record of delta tumor volume, compared to baseline (PET MRI 1) | At the 2nd PET (PET2), up to 28 months | |
Secondary | Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta SUVmax values | Record of delta SUVmax, compared to baseline (PET MRI 1) | At the 2nd PET (PET2), up to 28 months | |
Secondary | Description of the specific PET-MRI responses at mid-treatment of the neoadjuvant chemotherapy in terms of delta ADC values | Record of delta ADC, compared to baseline (PET MRI 1) | At the 2nd PET (PET2), up to 28 months | |
Secondary | Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta tumor volume | Record of delta tumor volume, compared to baseline (PET MRI 1) | At the 3rd PET (PET3), up to 28 months | |
Secondary | Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta SUVmax values | Record of delta SUVmax, compared to baseline (PET MRI 1) | At the 3rd PET (PET3), up to 28 months | |
Secondary | Description of the specific PET-MRI responses to neoadjuvant chemotherapy in terms of delta ADC values | Record of delta ADC, compared to baseline (PET MRI 1) | At the 3rd PET (PET3), up to 28 months | |
Secondary | Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta tumor volume | Record of delta tumor volume, compared to PET3 | At the 4th PET (PET4), up to 28 months | |
Secondary | Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta SUVmax values | Record of delta SUVmax, compared to PET3 | At the 4th PET (PET4), up to 28 months | |
Secondary | Description of the specific PET-MRI responses to neoadjuvant radiochemotherapy in terms of delta ADC values | Record of delta ADC, compared to PET3 | At the 4th PET (PET4), up to 28 months | |
Secondary | Propose standardized criteria to differentiate responders from non-responders | Record of clinical and iconographic data predictive of good response to treatment | Data record throughout the study, up to 28 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |